SmithKline Beecham (UK and US) combines healthcare services:
This article was originally published in Clinica
Executive Summary
SmithKline Beecham (UK/US) will combine its healthcare service businesses in a single division headed by Tadataka Yamada, chairman of the department of internal medicine at the University of Michigan medical centre. Dr Yamada will be responsible for SmithKline Beecham Clinical Laboratories; the pharmaceutical benefit management company Diversified Pharmaceutical Services; the mail order business Diversified Prescription Delivery; and the recently formed Disease Management group.
You may also be interested in...
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.